Supernus Pharmaceuticals, Inc.
SUPN
$50.21
$0.300.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 90.90% | -300.53% | 290.23% | -177.16% | -60.18% |
| Total Depreciation and Amortization | 0.85% | 16.14% | 4.78% | 8.16% | -6.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 541.10% | 146.30% | -60.85% | -47.03% | 447.47% |
| Change in Net Operating Assets | -4.38% | -528.12% | -17.36% | 371.12% | 34.95% |
| Cash from Operations | 132.21% | -205.35% | 91.30% | -31.09% | -17.03% |
| Capital Expenditure | -231.01% | 71.65% | -39.14% | -53.52% | -6.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -114.88% | 1,234.01% | -180.10% | 402.97% | 83.82% |
| Cash from Investing | -205.35% | 259.13% | -182.02% | 395.28% | 83.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -63.96% | 624.69% | 60.43% | -70.31% | 98.64% |
| Repurchase of Common Stock | 96.18% | -1,663.04% | 98.62% | -238.50% | -155.04% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 18.87% | 88.58% | -- | -- |
| Cash from Financing | -59.53% | 2,153.26% | 104.37% | -463.31% | 91.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -382.65% | -71.90% | -37.95% | 23.52% | 284.45% |